Calcitoninetherapie bij grote of recidiverende centrale reuzencelgranulomen van de onderkaak

Translated title of the contribution: Calcitonin therapy for large or recurrent central giant cell granulomas in the lower jaw

A. J W P Rosenberg*, A. N. Bosschaart, J. W G Jacobs, J. J. Wirds, R. Koole

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)

Abstract

In three patients, boys aged 4 and 3 years and a woman aged 18 years, central giant cell granuloma of the mandible was diagnosed. As an alternative to mutilating surgery all three patients were treated with calcitonin, the second one when he was 16 years old and after the tumour had recurred 5 times following extirpation. After an average therapy of 14 months, no recurrences were encountered. Mean follow-up was 8 months. In local biopsies mature bone tissue was seen during the first 3 months of therapy, slight changes of the levels of procollagen peptide type 1, parathormone and hydroxyproline in 24-hour urine were noticed, all within the normal limits. During and after termination of therapy serum calcium, phosphate and parathormone stayed within the normal range. Side effects consisted of flushes, nausea and vomiting. Calcitonin is still an experimental therapy for central giant cell granuloma, but may be a good alternative to mutilating surgery in case of large or multiple recurring tumours.

Translated title of the contributionCalcitonin therapy for large or recurrent central giant cell granulomas in the lower jaw
Original languageDutch
Pages (from-to)335-339
Number of pages5
JournalNederlands Tijdschrift voor Geneeskunde
Volume141
Issue number7
Publication statusPublished - 15 Feb 1997

Fingerprint

Dive into the research topics of 'Calcitonin therapy for large or recurrent central giant cell granulomas in the lower jaw'. Together they form a unique fingerprint.

Cite this